A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C

Launched by BORYUNG PHARMACEUTICAL CO., LTD · Dec 3, 2023

Keywords

ClinConnect Summary

This clinical trial is studying two medications, BR1018B and BR1018C, to see how effective and safe they are for people with essential hypertension (high blood pressure) and primary hypercholesterolemia (high cholesterol levels). The trial is currently recruiting participants and is open to adults aged 39 and older, regardless of gender. To be eligible, participants should have certain blood pressure and cholesterol levels, and those who are currently taking medication for these conditions may be asked to stop those medications for the duration of the study.

Participants in this trial can expect to undergo several evaluations to ensure they meet the study's criteria, including blood pressure and cholesterol tests. The study aims to find out if the combination of these two medications can help manage their conditions better than current treatments. If you're considering joining, it's important to know that there are specific health conditions that may exclude you from participating, such as certain types of high blood pressure or cholesterol related to other health issues. Overall, this trial could provide valuable information about new treatment options for managing high blood pressure and cholesterol.

Gender

ALL

Eligibility criteria

• • \<Inclusion Criteria\>
• • Screening Visit (V1)
• • Patients with essential hypertension and primary hypercholesterolemia
• • If patients are being treated with antihypertensive/antihyperlipidemic drugs at screening, they should be determined to be medically reasonable by investigator about discontinuing existing antihypertensive/antihyperlipidemic drugs during the clinical trial
• * Patients under the following criteria at screening:
• • Patients who meet a fasting triglyceride (TG) \< 400 mg/dL and LDL-C ≤ 250 mg/dL
• • Patients who meet the following criteria, depending on whether antihypertensive drugs were administered within the last 4 weeks
• • 1. Naïve : 140 mmHg ≤ MSSBP \< 180 mmHg and MSDBP \< 110 mmHg
• • 2. Use antihypertensive drugs : 130 mmHg ≤ MSSBP \< 180 mmHg and MSDBP \< 110 mmHg
• • Baseline Visit (V2)
• • Patients who meet the following criteria of blood pressure measured in selected reference arm at baseline (According to the clinical situation of each subject, Follow the blood pressure standards(Refer to 2022 The Korean Society of Hypertension Guideline))
• • 140 mmHg(or 130 mmHg) ≤ MSSBP \< 180 mmHg
• • MSDBP \< 110 mmHg
• • Patients who meet fasting serum lipid profile test levels (LDL-C and TG) correspond to cardiovascular risk and risk factors at baseline (Refer to 2022 Korean Guidelines for the Management of Dyslipidemia (the 5th edition))
• • \<Exclusion Criteria\>
• • Patients with a difference of SiSBP ≥ 20 mmHg and SiDBP ≥ 10 mmHg in blood pressure measured three times on both arms at screening(V1)
• • Patients with blood pressure results showing MSSBP ≥ 180 mmHg or MSDBP ≥ 110 mmHg at screening(V1, both arms) and baseline(V2, selected reference arm)
• • Patients with a history of secondary hypertension or suspected secondary hypertension; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, renal hypertension, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)
• • Patients with a history of secondary hyperlipidemia or suspected hyperlipidemia; (e.g., Chronic renal failure, nephrotic syndrome, dysproteinemia, obstructive liver disease, Cushing's syndrome, hypothyroidism, etc.)
• • Patients with hyportensive shock
• • Patients with orthostatic hypotension accompanied by symptoms